Table 3.
Physician-reported data on demographics, treatment pathways, and clinical assessment of patients who switched from adalimumab RP to ABP 501 (RP-ABP 501 switchers)
| RP-ABP 501 switchers | |
|---|---|
| N = 136 | |
| Demographics | |
| Age, years, mean (SD) | 40.6 (12.3) |
| Sex, male, n (%) | 75 (55.1) |
| Ethnicity, White/Caucasian, n (%) | 123 (90.4) |
| Treatment pathways | |
| Time from initial diagnosis to first receipt of ADA RP, months, median (IQR) | 10.0 (0.7, 30.0)a |
| Time duration on ABP 501, months, median (IQR) | 7.7 (5.1, 13.7) |
| Time duration on RP prior to switch to ABP 501, months, median (IQR) | 14.0 (6.2, 28.4) |
| Conventional therapy received prior to current ABP 501 therapyb, n (%) | |
| 5-Aminosalicylic acid | 72 (52.9) |
| Corticosteroids | 73 (53.7) |
| Immunomodulators | 49 (36.0) |
| Treatment regimen at time of consultation, n (%) | |
| Adalimumab monotherapy | 93 (68.4) |
| Adalimumab with conventional therapies | 43 (31.6) |
| 5-Aminosalicylic acid | 28 (20.6) |
| Corticosteroids | 4 (2.9) |
| Immunomodulator | 12 (8.8) |
| Clinical assessment reported by treating physicians | |
| Disease severity at time of consultation, n (%) | |
| Mild | 113 (83.1) |
| Moderate | 23 (16.9) |
| Severe | 0 (0.0) |
| Disease progression status at time of consultation, n (%) | |
| Improving | 50 (36.8) |
| Stable | 84 (61.8) |
| Deteriorating slowly | 1 (0.7) |
| Deteriorating rapidly | 1 (0.7) |
| Physician-assessed remission status at time of consultation, n (%) | |
| Clinical remissionc | 121 (89.0) |
| Not in clinical remission | 15 (11.0) |
| Treatment satisfaction reported by physicians, n (%) | |
| Satisfied | 134 (98.5) |
| Dissatisfied | 2 (1.5) |
ABP 501 adalimumab biosimilar, ADA adalimumab, IQR interquartile range, RP reference product, SD standard deviation
an = 135 patients with known diagnosis date
bTreatments received at any point between diagnosis and initiation of current ABP 501 therapy
c“Clinical remission” combines responses “Clinical/symptomatic remission, but full mucosal healing not achieved”, “Clinical/symptomatic remission, but mucosal healing currently unknown”, and “Clinical/symptomatic remission and full mucosal healing (histologic remission)”. “Not in clinical remission” combines responses “Not in remission” and “Full mucosal healing but symptoms remain”